Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INXN-1001 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| INXN-1001 | DRUG | Capsules given once daily for 14 days for 3 treatment cycles. |
| INXN-3001 | BIOLOGICAL | Intratumoral injection |
Inclusion Criteria: 1. Males or females of all races ≥ 18 years of age and ≤ 75 years of age; 2. Unresectable Stage III C (in transit) or Stage IV melanoma (M1a, M1b, M1c with LDH ≤ 2x ULN), arising from primary cutaneous, mucosal, or subungual melanoma of any tumor thickness or from an unknown pri...
Top 20 of 51 competitors
INXN-1001 is an investigational small molecule being studied for the treatment of melanoma. It is administered via intratumoral injections and is currently in Phase 1 clinical development. The drug is not yet approved and remains under investigation for this indication.
INXN-1001 is being developed by Alaunos Therapeutics, Inc., a biopharmaceutical company. The company is publicly traded on the NASDAQ under the ticker symbol TCRT. The drug is in Phase 1 clinical development for melanoma.
INXN-1001 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial of the drug has been completed, and it remains under investigation for the treatment of melanoma.
INXN-1001 has been studied in one clinical trial, identified as NCT00815607. This was a Phase 1, uncontrolled, open-label trial of intratumoral injections of INXN-3001 in subjects with Stage III or IV melanoma. The trial was completed in the United States and enrolled 12 participants.
INXN-1001 is not the same as INXN-3001. The completed clinical trial NCT00815607 evaluated intratumoral injections of INXN-3001, a different drug candidate. INXN-1001 is a separate investigational small molecule being developed by Alaunos Therapeutics for melanoma.